Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-576-1 | CAS number: 3148-73-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: - Study well documented, meets generally accepted scientific principles, acceptable for assessment - non-GLP
Data source
Reference
- Reference Type:
- publication
- Title:
- Pharmacokinetics of isoniazid metabolism in man.
- Author:
- Ellard GA & Gammon PT
- Year:
- 1 976
- Bibliographic source:
- J Pharmacokinet Biopharm. 1976 Apr;4(2):83-113.
Materials and methods
- Type of study / information:
- in vivo investigation of adsorption, distribution, metabolism and excretion in man
- Endpoint addressed:
- basic toxicokinetics
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- - study I:
• two volunteers, one a slow acetylator the second a rapid acetylator took (bw: 63 and 62 kg respectively), on successive occasions separated by at least a week, oral doses of 10, 50, and 250 mg isoniazid, 50 and 500 mg acetylisoniazid, 10 mg isoniazid plus 50mg acetylisoniazid, 25mg isonicotinic acid, 116 mg diacetylhydrazine, 74mg monoacetylhydrazine (as 190 mg monoacetylhydraziniumfumarate), and 750 mg sulfadimidine, respectively.
• urine collection up to 48 h
• blood sampling of the slow acetylator after ingestion of the highest doses of isoniazid, acetylisoniazid, and isonicotinic acid
- study II:
• oral doses of 20 mg isoniazid/kg taken by 17 subjects
• blood sampling at 3 and 6 h post dosing
• urine sampling at 0-2.5, 2.5-3.5, 3.5-5.5, and 5.5-6.5 h post dosing
- study III:
• 13 volunteers, dosed with 600 mg isoniazid in a matrix formulation
• urine collection up to 48 h post dosing
• 25 tuberculosis patients, oral doses of 300 mg isoniazid plus 150 mg thiacetazone on 2 consecutive days
• 24 h urine
- Determination of concentrations of parent substance and metabolites by spectrometric methods (colorimetry and fluorometry) - GLP compliance:
- no
Test material
- Reference substance name:
- N,N'-diacetylhydrazine
- EC Number:
- 221-576-1
- EC Name:
- N,N'-diacetylhydrazine
- Cas Number:
- 3148-73-0
- Molecular formula:
- C4H8N2O2
- IUPAC Name:
- N'-acetylacetohydrazide
- Details on test material:
- - Name of test material (as cited in study report): diacetylhydrazine
- Physical state: not reported
- Analytical purity: not reported, but synthesis method cited: G. A. Ellard, P. T. Gammon, and S. M. Wallace. The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine. Biochem. J. 126:449-458 (1972).
- Impurities (identity and concentrations): not reported
- Stability under test conditions: not reported
- Storage condition of test material: not reported
Constituent 1
Method
- Ethical approval:
- not specified
- Details on study design:
- Route of administration
- oral (unspecified), in water as vehicle
Duration and frequence of treatment
- study I: single oral exposure
- study II: single oral exposure
- study II:
• healthy volunteers: single oral exposure
• tuberculosis patients: oral doses at 2 consecutive days
Doses
- study I: 116 mg diacetylhydrazine (volunteers: 63 and 62 kg body weight)
- study II: 20 mg isoniazid/kg bw
- study II:
• healthy volunteers: 600 mg isoniazid per person
• tuberculosis patients: 300 mg isoniazid plus 150 mg thiacetazone per person
No. of participants
- study I: 2, 1 slow acetylator, 1 rapid acetylator
- study II: 17, 12 slow acetylators, 5 rapid acetylators
- study II:
• healthy volunteers: 13, 6 slow acetylators, 7 rapid acetylators
• tuberculosis patients: 25 tuberculosis patients - Exposure assessment:
- measured
- Details on exposure:
- TYPE OF EXPOSURE:
defined applied doses via the oral route (see above)
Results and discussion
- Results:
- Details on absorption
The rapidity of the urinary excretion rate of diacetylhydrazine indicates that it was very rapidly absorbed and distributed throughout the body. Absorption of diacetylhydrazine compounds was effectively complete.
Details on distribution in tissues
The rapidityof the urinary excretion rate of diacetylhydrazine indicates that it was very rapidly absorbed and distributed throughout the body. Absorption of diacetylhydrazine compounds was effectively complete.
Details on excretion
- maximal rates of urinary excretion occurred within 1 hr post administration of diacetylhydrazine, afterwards exponential decrease of the urinary excretion
- half-life of about 5 hr in urine.
- Excreted amounts:
• slow acetylator: 77% of the dose (unchanged)
• rapid acetylator: 86 % of the dose (unchanged)
• rate constants for the excretion of diacetylhydrazine: of 0.10 1/h and 0.12 1/h respectively
- "Further studies in tuberculosis patients with chronic renal failure have confirmed the conclusion that the terminal metabolites of isoniazid are isonicotinylglycine and diacetylhydrazine and have indicated that their elimination by extrarenal routes is minimal (G. A. Ellard and P. Sever, unpublished work)."
Details on metabolites
No metabolites of diacetylhydrazine were found.
Any other information on results incl. tables
- Only results relevant for diacetylhydrazine are reported. Results for Isoniazid are reported where helpful for comparison.
- Table 1:
Compound administered |
Dose (mg) |
Acetylator |
Fluid |
Period after dose° (hr) |
Elimination equation* |
Half-life (1/h) |
Diacetylhydrazine |
116 |
Slow |
Urine |
1.5-30.0 (7) |
1.02 - 0.058t |
5.2 ± 0.3 |
|
116 |
Rapid |
Urine |
1.5-30.0 (7) |
1.08 - 0.061t |
4.9 ± 0.5 |
*Equation relating the change with time (t) in hours of the logarithm10 of the concentration of the administered compound in the plasma its rate of elimination in the urine (percent dose excreted/hr).
- Table 2: Cumulative Urinary Excretion of lsoniazid and Diacetylhydrazine as percent administered dose.
Compound administered |
Isoniazid |
Diacetylhydrazine |
|||
Dose (mg): |
250 |
250 |
900 |
116 |
116 |
Collection period (hr): |
48 |
48 |
48 |
48 |
48 |
Acetylator status' |
S |
R |
S |
S |
R |
Compound recovered |
|||||
Acid-labile isoniazid |
34.0 |
16.5 |
39.9 |
- |
- |
Acetylisoniazid |
28.5 |
40.7 |
28.5 |
- |
- |
Diacetylhydrazine |
5.7 |
26.8 |
4.5 |
76.8 |
86.1 |
Total hydrazidesd |
68.2 |
84.0 |
72.9 |
76.8 |
86.1 |
- Table 3: Apparent first-order rate constants calculated for the conversion and excretion of isoniazid and the excretion of diacetylhydrazine
Compound |
Dose (mg) |
Process |
First-order rate constant (1/h) |
|
Slow acetylator |
Rapid acetylator |
|||
Isoniazid |
250 |
Acetylation |
0.11 |
0.39 |
|
900 |
|
0.09 |
|
|
900 |
Excretion and hydrazone formation |
0.085 |
|
|
900 |
Hydrolysis to isonicotinic acid |
0.02 |
|
Diacetylhydrazine |
116 |
Excretion |
0.10 |
0.12 |
Applicant's summary and conclusion
- Conclusions:
- Absorption, distribution, metabolism and excretion of isoniazid and its metabolites were tested in different experimental settings in humans. The single exposure was via the oral route with water as vehicle. In this entry only the results for diacetylhydrazine are regarded. Based on the development of urine levels diacetylhydrazine is absorbed to a high extent (> 77 %) in both volunteers after a dose of ca. 1.85 mg/kg bw. No metabolites of diacetyl hydrazine are detected. All hydrazines detected are identical to the parent diacetylhydrazine. The half-life is ca. 5 h both in the slow as well as in the rapid acetylator. Therefore bioccumulation is not to be expected in humans.
The study is considered to be relevant as it is well documented, meets generally accepted scientific principles and described the toxicokinetic of the test item in humans. The number of volunteers is limited. Nevertheless generall assumptions on the toxicokinetic behaviour of diacetylhydrazine can be deduced from this study. - Executive summary:
Absorption, distribution, metabolism and excretion of isoniazid and its metabolites were tested in different experimental settings in humans. The single exposure was via the oral route with water as vehicle. In this entry only the results for diacetylhydrazine are regarded. In study I two volunteers, one a slow acetylator the second a rapid acetylator (bw: 63 and 62 kg respectively), took on successive occasions separated by at least a week, oral doses of 10, 50, and 250 mg isoniazid, 50 and 500 mg acetylisoniazid, 10 mg isoniazid plus 50mg acetylisoniazid, 25mg isonicotinic acid, 116 mg diacetylhydrazine, 74 mg monoacetylhydrazine (as 190 mg monoacetylhydraziniumfumarate), and 750 mg sulfadimidine, respectively. Urine was collected up to 48 h post dosing, blood was sampled of the slow acetylator after ingestion of the highest doses of isoniazid, acetylisoniazid, and isonicotinic acid. In study oral doses of 20 mg isoniazid/kg were taken by 17 subjects, blood sampling occurred at 3 and 6 h post dosing and urine sampling at 0 -2.5, 2.5 -3.5, 3.5 -5.5, and 5.5 -6.5 h post dosing. In study III 13 volunteers were dosed with 600 mg isoniazid in a matrix formulation, urine collected up to 48 h post dosing. In addition 25 tuberculosis patients received oral doses of 300 mg isoniazid plus 150 mg thiacetazone on 2 consecutive days and urine was sampled up to 24 h post exposure.Concentrations of parent substance and metabolites were determined by spectrometric methods (colorimetry and fluorometry). Results of study II and III are not relevant for the toxicokinetic of diacetylhydrazine. Based on the measurement of urine levels diacetylhydrazine is absorbed to a high extent (> 77 %) in both volunteers after a dose of ca. 1.85 mg/kg bw. No metabolites of diacetylhydrazine are detected. all hydrazines detected are identical to the parent diacetylhydrazine. The half-life is ca. 5 h both in the slow as well as in the rapid acetylator. Therefore bioccumulation is not to be expected in humans.
The study is considered to be relevant as it is well documented, meets generally accepted scientific principles and described the toxicokinetic of the test item in humans. The number of volunteers is limited. Nevertheless generall assumptions on the toxicokinetic behaviour of diacetylhydrazine can be deduced from this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.